Schering/Novartis To Develop Once-Daily Inhalation Combination For Asthma, COPD
This article was originally published in The Pink Sheet Daily
Executive Summary
Fixed-dose therapy will combine Novartis' investigational beta2-agonist indacaterol with Schering-Plough's Asmanex.